Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > News
View:
Post by SkywalkerofLuke on May 31, 2023 3:42pm

News

Big step forward for small cap health tech company AGN.c AGNPF who’s up 10% coming off the announcement they were granted a patent in Japan for Treating Chronic Kidney Disease with drug NP-251 or Repirinast.


Repirinast has data showing it reduced fibrosis by 51% and showed an additive benefit to medicine blood pressure drug telmisartan in a mouse model.


A study published earlier this month found that CKD “is affecting as many as 40 per cent of the elderly population in Canada and other developed countries” meaning there’s clearly a huge opportunity in finding a new solution to CKD.


More on the NR in this CEO interview

https://www.youtube.com/watch?v=H04k_Ek6gPI

Be the first to comment on this post
Algernon Pharmaceuticals Inc.